Evaluación y Manejo del Cáncer de Mama Metastásico, Irresecable o Recurrente: 1er Consenso Nacional del Cáncer de Mama de la Sociedad Panameña de Oncología (SPO)
[Evaluación y Manejo del Cáncer de Mama Metastásico, Irresecable o Recurrente: 1er Consenso Nacional del Cáncer de Mama de la Sociedad Panameña de Oncología (SPO)]Alejandro Crismatt Zapata1, José Luis Amador Sosa2, Ignacio Veliz3, Mario Guardia3, Gaspar Pérez-Jiménez3
1. Instituto Oncógico Panamá Centro Hemato Oncológico Panamá; 2. Instituto Oncógico Panamá (ION) Centro Hemato Oncológico Panamá (CHOP);
Descargas
Resumen
[Evaluation and Management of Metastatic, Irresectable or Recurrent Breast Cancer: 1st National Consensus of Breast Cancer of the Panamanian Society of Oncology (SPO)]
Resumen
El cáncer de mama metastásico es una enfermedad heterogénea, con poca probabilidad de ser curada; sin embargo, con el advenimiento de nuevas terapias sistémicas se ha conseguido una mejoría sustancial en la supervivencia global [1-3]. La mediana de supervivencia global está entre dos a tres años, con rangos que van de pocos meses a muchos años [4]. La selección de la estrategia terapéutica dependerá tanto del fenotipo tumoral como de factores clínicos. La idea general es dar el tratamiento lo más personalizado posible. Para la mayoría de las pacientes con cáncer de mama metastásico las bases del tratamiento son la terapia sistémica y los mejores cuidados de soporte; pero también hay pacientes que se benefician del control local regional [5-6].
Summary
Metastatic breast cancer is a heterogeneous disease, with little chance of being cured; however, with the advent of new systemic therapies, a substantial improvement in overall survival has been achieved [1-3]. The median overall survival is between two to three years, with ranges ranging from a few months to many years. [4] The selection of therapeutic strategy will depend on both the tumor phenotype and clinical factors. The general idea is to give the treatment as personalized as possible. For the majority of patients with metastatic breast cancer, the bases of treatment are systemic therapy and the best support care; but there are also patients who benefit from local regional control [5-6].
Abstract
[Evaluation and Management of Metastatic, Irresectable or Recurrent Breast Cancer: 1st National Consensus of Breast Cancer of the Panamanian Society of Oncology (SPO)]
Resumen
El cáncer de mama metastásico es una enfermedad heterogénea, con poca probabilidad de ser curada; sin embargo, con el advenimiento de nuevas terapias sistémicas se ha conseguido una mejoría sustancial en la supervivencia global [1-3]. La mediana de supervivencia global está entre dos a tres años, con rangos que van de pocos meses a muchos años [4]. La selección de la estrategia terapéutica dependerá tanto del fenotipo tumoral como de factores clínicos. La idea general es dar el tratamiento lo más personalizado posible. Para la mayoría de las pacientes con cáncer de mama metastásico las bases del tratamiento son la terapia sistémica y los mejores cuidados de soporte; pero también hay pacientes que se benefician del control local regional [5-6].
Summary
Metastatic breast cancer is a heterogeneous disease, with little chance of being cured; however, with the advent of new systemic therapies, a substantial improvement in overall survival has been achieved [1-3]. The median overall survival is between two to three years, with ranges ranging from a few months to many years. [4] The selection of therapeutic strategy will depend on both the tumor phenotype and clinical factors. The general idea is to give the treatment as personalized as possible. For the majority of patients with metastatic breast cancer, the bases of treatment are systemic therapy and the best support care; but there are also patients who benefit from local regional control [5-6].
Citas
[1] Stockler M, Wilcken N, Ghersi D, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000; 26(3): p. 151 -168.
[2] Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000; 18(12): p. 2395 - 2405.
[3] Amir E, Clemons M, Purdie C, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012; 38(6): p. 708-14.
[4] De Dueñas E, Hernández A, Zotano A, et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM ConvertHER study. Breast Cancer Res Treat. 2014; 143(3): p. 507-15.
[5] Hortobagyi G, Smith T, Legha S, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983; 1(12): p. 776 -86.
[6] Clark G, Sledge G, Osborne C, et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987; 5(1): p. 55 -61.
[7] Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998; 16(7): p. 2401 - 8.
[8] Robertson J, Dixon A, Nicholson R, et al. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat. 1992; 22(3): p. 221 -227.
[9] Barrios C, Sampaio C, Vinholes J, et al. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol. 2009; 20(7): p. 1157 -1162.
[10] Stuart-Harris R, Shadbolt B, Palmqvist C, et al. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors. Breast. 2009; 18(6): p. 351-355.
[11] Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33): p. 5287 - 5312.
[12] Taylor S, Gelman R, Falkson G, et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med. 1986; 104(4): p. 455 - 461.
[13] The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol. 1986; 4(2): p. 186-93.
[14] Stockler M, Wilcken N, Ghersi D, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000; 26(3): p. 151-68.
[15] Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 2017. 2017; 8(2): p. 120-134.
[16] Dhesy-Thind S, Fletcher C, Blanchette P, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017; 35(18): p. 2062-2081.
[17] Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011. 2011; 29(16): p. 2144-9.
[18] Park Y, Jung K, Im S, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013; 31(14): p. 1732-9.
[19] Vogel C, Schoenfelder J, Shemano I, et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995; 13(5): p. 1123-9.
[20] Finn R, Martin M, Rugo HS H, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375: p. 1925-1936.
[21] Hortobagyi G, Stemmer S, Burris H, et al. Ribociclib as First-Line Therapy for HR-Positive. N Engl J Med. 2016; 375: p. 1738-1748.
[22] Goetz M, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017; 35: p. 3638-3646.
[23] Robertson F, Bondarenko I, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016; 388: p. 2997-3005.
[24] Cristofanilli M, Turner N, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis. Lancet Oncol. 2016; 4: p. 425-439.
[25] Harbeck N, Iyer S, Turner N. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016; 27(6): p. 1047-1054.
[26] Piccart M, Hortobagyi G, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014; 25(12): p. 2357-62.
[27] Klijn J, Beex L, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000; 92(11): p. 903 - 911.
[28] Taylor C, Green S, Dalton W, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998; 16(3): p. 1994-1999.
[29] Sunderland M, Osborne C. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991. 1991; 9(7): p. 1283 - 1297.
[30] Swain S, Kim K, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14: p. 461–471.
[31] Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011; 29(3): p. 264-71.
[32] Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2positive advanced breast cancer. N Engl J Med. 2012; 367: p. 1783–1791.
[33] Krop I, Kim S, Martin A, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017; 18(6): p. 743-754.
[34] Robson M, Im S, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017; 377(6): p. 523 - 533.
[35] Tasleem S, Bolger J, Kelly M. The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact. Ir J Med Sci. 2018; 187(4): p. 1009-1020.
[36] Pagani O, Senkus E, Wood W, et al. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? NCI: Journal of the National Cancer Institute. 2010; 102(7): p. 456–463.
[37] Tosello G, Torloni M, Mota B, et al. Breast surgery for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews. 2018; 3: p. Art. No.: CD011276.
[38] Poggio F, Lambertini M, De Azambuja E. Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do. ESMO Open. 2018; 3: p. e000324.
[39] Rashid O, Takabe K. Does Removal of the Primary Tumor in Metastatic Breast Cancer Improve Survival? J Womens Health (Larchmt). 2014; 2(23): p. 184-8.
[40] Sze W, Shelley M, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev. 2004;(2):CD004721. Cochrane Database Syst Rev. 2004; 2: p. CD004721.
[41] Cardoso F, Bedard P, Winer E, et al. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. J Natl Cancer Inst. 2009; 101(17): p. 1174-1181.
[42] Müller-Riemenschneider F, Bockelbrink A, Ernst I, et al. Stereotactic radiosurgery for the treatment of brain metastases. Radiother Oncol. 2009; 91(1): p. 67-74.
[43] Ricardi U, Badellino S, Filippi A. Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res. 2016; 57(Suppl 1): p. i58–i68.
[44] Cho S, Kitisin K, Buck D, et al. Transcatheter Arterial Chemoembolization Is a Feasible Palliative Locoregional Therapy for Breast Cancer Liver Metastases. International Journal of Surgical Oncology. 2010; p. Article ID 251621.
[45] Lin Y, Médioni J, Amouyal G, et al. Doxorubicin-loaded 70-150 μm microspheres for liver-dominant Metastatic Breast Cancer: Results and Outcomes of a Pilot Study. Cardiovasc Intervent Radiol. 2017.; 40(1): p. 81-89.
[46] Barral M, Auperin A, Hakime A, et al. Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients. Cardiovasc Intervent Radiol (2016) 39: 885. Cardiovasc Intervent Radiol. 2016; 39: p. 885-93.
[47] Gomes B. Palliative Care: If It Makes a Difference, Why Wait? J Clin Oncol. 2015; 33(13): p. 1420-1.
[48] Distelhorst S, Cleary JF J, Ganz P, et al. Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. Lancet Oncol. 2015; 16(3): p. 137-47.
[49] Ferrell B, Temel J, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(1): p. 96-112.
[50] Rabow M, Small R, Jow A, et al. The value of embedding: integrated palliative care for patients with metastatic breast cancer. Breast Cancer Res Treat. 2018; 167(3): p. 703 - 708.
Licencia
Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.
